首页 | 本学科首页   官方微博 | 高级检索  
     


Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational,randomised, double-blind,phase 3 trial
Authors:Corneel Coens  Stefan Suciu  Vanna Chiarion-Sileni  Jean-Jacques Grob  Reinhard Dummer  Jedd D Wolchok  Henrik Schmidt  Omid Hamid  Caroline Robert  Paolo A Ascierto  Jon M Richards  Celeste Lebbé  Virginia Ferraresi  Michael Smylie  Jeffrey S Weber  Michele Maio  Andrew Bottomley  Srividya Kotapati  Alexander M M Eggermont
Affiliation:1. EORTC Headquarters, Brussels, Belgium;2. IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy;3. Hôpital de la Timone, Marseille, France;4. University of Zürich Hospital, Zürich, Switzerland;5. Memorial Sloan Kettering Cancer Center, New York, NY, USA;6. Aarhus University Hospital, Aarhus, Denmark;7. The Angeles Clinic and Research Institute, Los Angeles, CA, USA;8. Gustave Roussy Cancer Campus Grand Paris, Villejuif, France;9. Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy;10. Oncology Specialists S C, Park Ridge, IL, USA;11. Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Paris;12. Istituti Fisioterapici Ospitalieri, Rome, Italy;13. Cross Cancer Institute, Edmonton, AB, Canada;14. H Lee Moffitt Cancer Center, Tampa, FL, USA;15. University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;p. Bristol-Myers Squibb, Wallingford, CT, USA;q. Bristol-Myers Squibb, Braine-l''Alleud, Belgium;r. European Institute of Oncology, Milan, Italy
Abstract:
Keywords:Correspondence to: Mr Corneel Coens   EORTC Headquarters   Brussels 1200   Belgium
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号